Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
View ORCID ProfileManaf AlQahtani, View ORCID ProfileAbdulkarim Abdulrahman, Abdulrahman Almadani, Salman Yousif Alali, Alaa Mahmood Al Zamrooni, Amal Hamza Hejab, Ronán M Conroy, Pearl Wasif, Stephen L Atkin, Sameer Otoom, Manal Abduljalil
doi: https://doi.org/10.1101/2020.11.02.20224303
Manaf AlQahtani
1National Task Force for Combating the Corona Virus (COVID-19), Bahrain
2Bahrain Defence Force Hospital, Bahrain
MDAbdulkarim Abdulrahman
1National Task Force for Combating the Corona Virus (COVID-19), Bahrain
3Sheikh Mohammed bin Khalifa Cardiac Centre, Bahrain
MDAbdulrahman Almadani
2Bahrain Defence Force Hospital, Bahrain
MDSalman Yousif Alali
1National Task Force for Combating the Corona Virus (COVID-19), Bahrain
2Bahrain Defence Force Hospital, Bahrain
MDAlaa Mahmood Al Zamrooni
4Salmaniya Medical Complex, Manama, Bahrain
MDAmal Hamza Hejab
1National Task Force for Combating the Corona Virus (COVID-19), Bahrain
MDRonán M Conroy
5Royal College of Surgeons in Ireland, Dublin, Ireland
PhDPearl Wasif
6Royal College of Surgeons in Ireland-Bahrain
BScStephen L Atkin
6Royal College of Surgeons in Ireland-Bahrain
PhDSameer Otoom
6Royal College of Surgeons in Ireland-Bahrain
PhDManal Abduljalil
2Bahrain Defence Force Hospital, Bahrain
MD![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
Data will be made available upon reasonable request
Posted November 04, 2020.
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
Manaf AlQahtani, Abdulkarim Abdulrahman, Abdulrahman Almadani, Salman Yousif Alali, Alaa Mahmood Al Zamrooni, Amal Hamza Hejab, Ronán M Conroy, Pearl Wasif, Stephen L Atkin, Sameer Otoom, Manal Abduljalil
medRxiv 2020.11.02.20224303; doi: https://doi.org/10.1101/2020.11.02.20224303
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
Manaf AlQahtani, Abdulkarim Abdulrahman, Abdulrahman Almadani, Salman Yousif Alali, Alaa Mahmood Al Zamrooni, Amal Hamza Hejab, Ronán M Conroy, Pearl Wasif, Stephen L Atkin, Sameer Otoom, Manal Abduljalil
medRxiv 2020.11.02.20224303; doi: https://doi.org/10.1101/2020.11.02.20224303
Subject Area
Subject Areas
- Addiction Medicine (329)
- Allergy and Immunology (648)
- Anesthesia (173)
- Cardiovascular Medicine (2484)
- Dermatology (209)
- Emergency Medicine (384)
- Epidemiology (11947)
- Forensic Medicine (10)
- Gastroenterology (714)
- Genetic and Genomic Medicine (3874)
- Geriatric Medicine (358)
- Health Economics (648)
- Health Informatics (2503)
- Health Policy (963)
- Hematology (350)
- HIV/AIDS (812)
- Medical Education (384)
- Medical Ethics (106)
- Nephrology (411)
- Neurology (3638)
- Nursing (204)
- Nutrition (542)
- Oncology (1887)
- Ophthalmology (549)
- Orthopedics (229)
- Otolaryngology (298)
- Pain Medicine (240)
- Palliative Medicine (71)
- Pathology (459)
- Pediatrics (1066)
- Primary Care Research (434)
- Public and Global Health (6305)
- Radiology and Imaging (1335)
- Respiratory Medicine (845)
- Rheumatology (388)
- Sports Medicine (333)
- Surgery (424)
- Toxicology (51)
- Transplantation (179)
- Urology (152)